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Background: Since the advent of cardiopulmonary bypass, many efforts have been made to avoid the
complications related with it. Any component of the pump participates in occurrence of these adverse events, one
of which is the type of prime solution. In this study, we aimed to compare the effects of 6% hydroxyethyl starch
130/0.4 with a commonly used balanced electrolyte solution on postoperative outcomes following coronary bypass
surgery.
Methods: Two hundred patients undergoing elective coronary bypass surgery were prospectively studied. The
patients were randomized in to two groups. First group received a balanced electrolyte solution and the second
group received 6% hydoxyethyl starch 130/0.4 as prime solution. The postoperative outcomes of the patients were
studied.
Results: The mean age of the patients was 61.81 ± 10.12 in the crystalloid group whereas 61.52 ± 9.29 in the HES
group. There were 77 male patients in crystalloid group and 74 in HES group. 6% hydroxyethyl starch 130/0.4 did
not have any detrimental effects on renal and pulmonary functions. The intensive care unit stay and postoperative
hospital length of stay were shorter in hydroxyethyl starch group (p < 0.05 for each). Hydroxyethyl starch did not
increase postoperative blood loss, amount of blood and fresh frozen plasma used, but it decreased platelet
concentrate requirement. It did not have any effect on occurrence of post-coronary bypass atrial fibrillation (p > 0.05).
Conclusions: 6% hydroxyethyl starch 130/0.4 when used as a prime solution did not adversely affect postoperative
outcomes including renal functions and postoperative blood transfusion following coronary bypass surgery.
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Increased number of patients are undergoing coronary
artery bypass grafting (CABG) and efforts to prevent ad-
verse events and improve outcomes are done. One of
the most important problems following cardiac surgery
is renal failure. Use of cardiopulmonary bypass (CPB),
blood and constituents, various drugs and infusion of
large volumes of fluids influence the renal functions.
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reproduction in any medium, provided the orincreased mortality and morbidity [1]. Modifications on
every component of CPB are studied to decrease the risk
of renal failure particularly related with CPB use.
Cardiopulmonary bypass priming solution and volume
are of special importance since it directly affects renal
functions. Hemodilution due priming volume, continu-
ous flow pattern of CPB, use of various drugs during
CPB and occurrence of systemic inflammatory response
syndrome (SIRS) adversely affect renal functions [2].
Hydroxyethyl starch (HES) is commonly used in current
practice as a volume expander in trauma, shock, cardiac
and other major surgeries and vast numbers of reports are
being published with conflicting results. Still there is no
consensus on the renal effects of HES solutions.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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document the effects of 6% hydroxyethyl starch 130/0.4
on postoperative outcomes and occurrence of atrial
fibrillation (AF) in patients undergoing on-pump CABG
surgery.
Methods
A prospective and randomized study has been carried
out. The study was approved by the “Medicana Inter-
national Ankara Hospital Ethics Committee” and written
informed consent was taken from every patient. The
only inclusion criteria were isolated on-pump CABG
procedure. Both genders were accepted. There were no
age or weight restrictions. Exclusion criteria were; repeat
cardiac surgery, emergent surgery, preoperative coagulation
disorder, preoperative clopidogrel use, preoperative con-
gestive heart failure, preoperative renal dysfunction (serum
creatinine > 1.3 mg/dl), preoperative hepatic dysfunction
(serum aspartate/alanine amino transferase > 40U/l), pre-
operative electrolyte imbalance, history of pancreatitis and
known hypersensitivity to HES. Between October 2011 and
April 2012, after the inclusion and exclusion criteria were
employed 200 isolated CABG cases were studied. The
patients were then randomized as follows: each patient
was given a number according to chronological order
beginning from 1. The odd numbered patients (n:100) were
administered 6% HES 130/0.4 in 0.9% sodium chloride
(VoluvenW %, Fresenius Kabi, Bad Homburg, Germany) as
CPB prime solution and even numbered patients (n:100)
were administered a balanced multielectrolyte solution
(Isolyte-MW, Eczacıbaşı-Baxter, İstanbul: dextrose monohy-
drate, 40 mEq/l sodium, 40 mEq/l chloride, 35 mEq/l
potassium, 15 mEq/l phosphate, 20 mEq/l acetate; 400 -
mOsm/l, 170 kCal/l).
Preoperative acetylsalicylic acid 100 mg/day was contin-
ued in all patients prior to the day of surgery. All patients
were premedicated with 10 mg of oral diazepam.
Anesthesia was induced with etomidate 2 mg/kg, fentanyl
1 μg/kg, vecuronium 1 mg/kg; isofluorane 1 MAC was
used for anesthesia maintenance. Intraoperative arterial
and central venous pressure monitorization were done.
The cardiopulmonary bypass (CPB) circuit was
primed with 1,500 ml of determined solution. In both
groups 5,000 units of heparin was added. After anti-
coagulation with heparin (300 U/kg), activated clotting time
(ACT) was kept over 400 seconds. CPB was established
using a roller pump with a membrane oxygenator (Dideco
Compactflo Evo, Sorin Group, Mirandola Modena, Italy).
The average flow rate varied from 2.3 to 2.4 l/min/m2. Sur-
gery was performed under mild hypothermia (33°C). Mean
arterial pressure was kept between 45 to 70 mm Hg.
All patients were rewarmed to 37°C (nasopharyngeal
temperature) before weaning from CPB. Heparin was
neutralized with 1:1 protamine sulfate.Cold (4-8°C) blood cardioplegia of 1000 ml (25 mEq/l
potassium) was administered after aortic cross clamping,
and 500 ml repeat doses were given every 15 to 20 minutes
(antegrade and from venous bypass grafts, retrograde in
patients with left main coronary disease). Terminal
warm blood cardioplegia (36-37°C) was given prior to
aortic clamp release.
The operation room temperature was kept at 20-21°C.
In postoperative period rate of fluid infusions were ad-
justed according to hemodynamic measurements. Central
venous pressure was maintained between 8–12 mm Hg.
Packed red blood cell was given if the hematocrit level
fell below 25%. Fresh frozen plasma and platelet concen-
trates were administered in cases of documented postoper-
ative coagulation abnormalities (international normalized
ratio > 1.5, activated partial thromboplastin time > 60 s and
platelet count < 80,000/mm3) or suspected postoperative
platelet dysfunction and factor deficiency.
The decision for re-exploration for hemorrhage was
made when 200 ml/hour of drainage was documented
on two consecutive hours despite measures taken or
more than 300 ml/hour drainage.
On postoperative day 1, all patients were administered
metoprolol (50 mg/day) or carvedilol (3.125-6.25 mg/day)
and N-acetylcysteine (oral: creatinine < 1.3 mg/dl; intra-
venous: creatinine > 1.3 mg/dl) and continued. All patients
were routinely administered low molecular weight heparin
in prophylactic dose.
Atrial fibrillation was diagnosed based on electrocar-
diogram. All patients were ECG monitored continuously
during the intensive care unit (ICU) stay and for the first
24 hours in the ward. Soon ECG was immediately
performed in cases of irregular pulse, palpitation or
symptoms related with possible AF.
In cases with AF, if required intravenous metoprolol
was administered for heart rate control. For rhythm
control, intravenous amiodarone was administered as
intravenous 300 mg loading dose in 1 hour, followed by
900 mg in 24 hours and followed by oral amiodarone
200 mg three times a day. In refractory cases 450 mg
additional intravenous infusion was given in 12 hours
period. If no response was noted after 48 hours, elec-
trical cardioversion was employed. Low molecular
weight heparin dosage was switched to therapeutic
interval. In cases of permanent AF development, oral
warfarin was administered.
Primary outcome variables included mean time to
extubation, ICU and postoperative hospital length of stay,
incidence of renal dysfunction (based on the finding that
peak creatinine value was 1.5 or greater times the pre-
operative value), postoperative stroke, postoperative total
amount of blood loss, postoperative exploration for
hemorrhage, number of used blood and blood products
and in hospital mortality.
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Statistical analyses were performed using SPSS software
for Windows version 17.0 (Statistical Package for the
Social Sciences Inc, Chicago, IL, USA). Continuous vari-
ables were expressed as ‘mean values ± standard deviation
(SD)’. Categorical variables were expressed as number and
percentages. Demographic characteristics and outcomes
of the groups were compared using “independent samples
t-test” for continuous variables, and, ‘chi-square test’ and
‘Fisher’s exact test’ for categorical variables. Statistical sig-
nificance was set as ‘p < 0.05’.Results
The mean age of the patients was 61.81 ± 10.12 in the
crystalloid group whereas 61.52 ± 9.29 in the HES group
(p > 0.05). There were 77 male patients in crystalloid
group and 74 in HES group (p > 0.05). Preoperative
demographic findings and intraoperative characteristics







Mean ± SD Mean ± SD
Age 61.81 ± 10.12 61.52 ± 9.29 0.833
BMI (kg/m2) 27.88 ± 3.96 29.02 ± 4.61 0.063
LVEF (%) 53.72 ± 10.81 52.33 ± 11.08 0.370
Cross-clamp time (min) 53.57 ± 20.12 55.58 ± 17.22 0.449
CPB time (min) 79.69 ± 27.93 82.57 ± 23.98 0.435
Graft # 3.22 ± 1.06 3.10 ± 0.90 0.390
n:% n:% p value**
Patient Total 100 100
Male sex 77 74 0.622
Current/Ex-smoker 67 63 0.553
Diabetes Mellitus 46 42 0.569
Hypertension 65 62 0.659
Dyslipidemia 79 76 0.611
Preoperative β-blocker use 40 47 0.318
Peripheral Arterial Diseasea 1 6 0.118***
Stroke - 1 1.000***
Carotid Diseaseb 7 5 0.552***




aHistory of therapeutic vascular intervention, history of claudication,
angiography/non-invasive proven peripheral arterial disease.
bHistory of carotid intervention or angiographic/non-invasive proven >40%
stenosis of either carotid.
BMI: body mass index, LVEF: left ventricular ejection fraction.
CPB: cardiopulmonary bypass, COPD: chronic obstructive pulmonary disease.There was not a statistically significant difference
when intubation times, postoperative drainage, amount
of red blood cell and fresh frozen plasma used and post-
operative adverse events (renal failure, stroke, mortality)
were compared. Number of platelet concentrate used
was lower in the HES group (p < 0.05). Postoperative
ICU and postoperative hospital length of stay were
shorter in HES group (p < 0.05) (Table 2). No mortality
was noted during the study period.
Atrial fibrillation incidence was 19% in HES group
whereas 15% in crystalloid group (p > 0.05).Discussion
Coronary bypass surgery is the most frequently performed
cardiac operation worldwide and modifications are
made in order to maintain more reasonable results
[3]. Various improvements are recorded on surgical
techniques, CPB devices, drugs and perioperative
management. Postoperative outcomes especially renal
functions are very important in these patients due to
the direct relation between mortality and morbidity.






Mean ± SD Mean ± SD p value*
ICU intubation time, hours 10.38 ± 9.04 9.38 ± 2.64 0.290
Length Of Stay
ICU, hours 47.93 ± 12.01 45.25 ± 5.86 0.046
Postoperative, days 6.14 ± 2.55 5.47 ± 1.20 0.019
Drainage tubes removed,
hours
36.36 ± 10.39 36.12 ± 13.32 0.886
Total amount of drainage,
ml
741.75 ± 448.58 680.30 ± 332.92 0.273
Number of FFP used 1.05 ± 1.32 1.02 ± 1.40 0.877
Number of packed RBC
used
1.82 ± 1.65 1.63 ± 1.50 0.397
Number of PC used 0.61 ± 1.92 0.15 ± 0.98 0.035




Postoperative AF 15 19 0.451***
Renal Dysfunctiona 6 9 0.421
Postoperative Stroke 1 1 1.000
*Independent samples t-test.
** Fisher’s exact test.
***chi-square test.
adefined when peak creatinine value was 1.5 or greater times the
preoperative value.
ICU: intensive care unit, FFP: fresh frozen plasma.
RBC: red blood cell, PC: platelet concentrate.
AF: atrial fibrillation.
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HES solutions as priming solution.
During CPB, derangements in multiple organ systems
occur, and the resultant SIRS is the main reason for
postoperative morbidity and mortality. The main causes
of these changes are the contact with foreign surfaces,
changes in coagulation and fibrinolytic systems, activation
of the complement system, hemodilution and hypothermia.
Also endotoxemia and ischemia-reperfusion injury have
adverse effects. Any component of CPB system has direct
influence on postoperative outcomes. Two of the most
important components are the type and volume of priming
solution [4,5].
Various types of priming solutions have been researched
and employed, but today still there is no consensus on
ideal priming solution in clinic use that can prevent SIRS,
fluid retention and hypercoagulation. Hydroxyethyl starch
is used very frequently as a priming solution in cardiovas-
cular surgery and as a volume expanding agent in peri-
operative care and in trauma. Many reports were
published concerning the results following HES use, but
very recently some of them were retracted. This shaded
the formed concept on HES solutions and created a
doubtful era. Today, there is still a controversy on the
effects of HES particularly on coagulation and renal
functions.
Choi et al. [6] studied the effects of HES when used as
a priming solution in comparison with human albumin
and they did not find any difference on coagulation vari-
ables, postoperative blood loss, transfusion requirements
and inflammatory response. In our study, we compared
HES with a commonly used crystalloid solution and
found similar results; HES did not cause detrimental
results on postoperative outcomes.
Liou et al. [7] reported comparison between three dif-
ferent priming solutions; ringers lactate, human albumin
and %10 HES. Time to extubation, ICU stay and hospital
stay did not differ among the groups. The inflammatory
cytokines TNF-α, IL-1β and IL-6 levels were also mea-
sured following CPB and no statistically significant dif-
ference was reported. There was statistically significant
difference in postoperative body weight gain, HES and
human albumin groups caused less weight gain com-
pared to ringers lactate. This was because hypo-oncotic
prime solutions lead to interstitial fluid expansion more
than colloids. We also documented similar results, but
we also studied postoperative outcomes. We did not
study the inflammatory cytokines.
Kuitunen et al. [8] reported the effects of HES used for
priming on coagulation and concluded that HES use in-
creased blood loss. They revealed that less stable thrombi
were formed documented with thromboelastography.
They also concluded that HES in cardiac surgery may
increase blood loss. In our study, we did not find anydifference concerning the blood loss between the crystal-
loid and HES groups, HES did not adversely affect postop-
erative bleeding.
Tiryakioglu et al. [9] designed a similar study of prime
solutions and compared ringers lactate with HES. They
documented unfavorable effects of HES on renal func-
tions, but the urea and creatinine levels were in the
normal range in both groups. They found no statistical
difference in amount of postoperative bleeding, time to
extubation, intensive care unit stay and discharge times.
They only noted statistically significant difference in net
volume balance in favor of HES group. We did not
document any adverse effect on renal functions.
Yap et al. [10] studied gelatin and HES as prime solu-
tions and compared postoperative outcomes like intraocu-
lar pressure, blood profile and blood loss. They designated
intraocular pressure as a marker to determine plasma
oncotic pressure and they found that HES had had signifi-
cant favorable results compared to gelatin. There was no
difference concerning blood profile, blood loss and other
postoperative outcomes.
In a meta-analysis, it was documented that use of HES
did not cause any impairment in renal functions and also
no difference was found considering the risk of complica-
tions, reoperation and mortality [11]. Very recently,
Akkucuk et al. [12] documented their results on use of
HES 130/0.4 on pediatric patients undergoing CPB and re-
vealed no adverse effects on renal functions and other
events.
In cardiac surgery, the effects of HES solutions also
were studied for volume replacement in the postopera-
tive period. The results of the studies were similar to
those when HES solutions were used for priming. There
were no adverse effects documented on postoperative
coagulation parameters and postoperative renal func-
tions [13,14].
The effects of HES on AF can be regarded as a special
issue. Atrial fibrillation is the most common rhythm dis-
turbance following cardiac surgery and many efforts are
being made to reduce the risk of occurrence of AF. It was
revealed that there was a strong correlation between the
AF and inflammation [15-17]. The anti-inflammatory
effects of HES solutions have been documented [18,19]. In
our study, we also studied the effects of HES used as a
prime solution on occurrence of postoperative AF. We
did not note any difference between the groups.
Conclusions
In this prospective randomized study, we did not docu-
ment any difference between HES and crystalloid solu-
tions used for CPB priming regarding postoperative
outcomes like postoperative bleeding, renal functions and
the use of blood and FFP. The number of used PC was
less and the hospital length of stay and ICU stay were
Gurbuz et al. Journal of Cardiothoracic Surgery 2013, 8:71 Page 5 of 5
http://www.cardiothoracicsurgery.org/content/8/1/71shorter in HES group. The results may differ in high risk
patient groups and further studies with increased number
of patients should be made particularly on patients with
renal failure and coagulation disorders.
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